Being able to identify the earliest stages of disease and treat it with ultimate precision will help doctors treat patients better and help patients recover faster.


Over the past year scientists have developed 3D printed enzyme powered nanobots that can surf through the body’s bloodstream looking for and treating disease, and brain controlled nanobots that release drugs inside cockroaches. Now though scientists in the UK have developed tiny, remote controlled, micro “biohybrid” robots with the ability to release cancer targeting drugs, which they hope will one day be used to diagnose disease and administer drugs inside the human body.


AI has learnt to predict heart attacks more accurately than doctors


The biohybrid robots are so called because they’re made up of biological cells that have useful “engineered features” added on, in this case namely magnetic particles that allow them to be guided around the body. Despite their highly technical capability the robots the team built are made from Spirulina algae, a product that’s more recognisable as a health food product than a building material.



“Rather than fabricate functional micro biohybrid robots from scratch using intricate laboratory techniques and processes, we set out to directly engineer smart materials in nature,” said Professor Li Zhang, an engineer at the Chinese University of Hong Kong who contributed to the Science Robotics study, and as a result they were able to make use of the algae’s intrinsic properties.


Humanoid ATLAS robot crams millions of years of evolution into two years


“For instance, because these biohybrid bots have a naturally fluorescent biological interior and magnetic iron-oxide exterior, we can track and actuate a swarm of those agents inside the body quite easily using fluorescence imaging and magnetic resonance imaging,” said Professor Zhang.

This meant the scientists were able to control the robots remotely using magnetism as they moved them to sites in the stomachs of rats where they were used to release the cancer fighting compounds prescicely to the right area, meaning they could have the potential to treat disease.


The UK FCA could become the world's first AI robo-regulator


“Creating robotic systems which can be propelled and guided within the body has been and still is a holy grail in the field of delivery system engineering,” said Nanomedicine researcher Professor Kostas Kostarelos, another team member from the University of Manchester.

The robots are also able to sense changes in the body associated with the onset of illness, an ability that could make them useful tools for diagnosis.

About author

Matthew Griffin

Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, Viacom, and WIRED, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.

Your email address will not be published. Required fields are marked *